These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 27170387)

  • 1. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
    Silveira MG; Lindor KD
    Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
    Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrates and cholestasis.
    Ghonem NS; Assis DN; Boyer JL
    Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
    Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
    Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary biliary cirrhosis and bile acids.
    Corpechot C
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis.
    Akepati PR; Gochanour EM
    Expert Opin Investig Drugs; 2024 Jun; 33(6):627-638. PubMed ID: 38676426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
    Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
    Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
    Beuers U; Trauner M; Jansen P; Poupon R
    J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Parés A
    Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
    Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
    Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.